Dangerous dynamic duo: Lactic acid and PD-1 blockade

Area of Science:

• Immunology
• Oncology
• Cancer Metabolism

Background:

• Immune checkpoint inhibitors (ICIs) like PD-1 blockade have revolutionized cancer treatment.
• Resistance to PD-1 blockade remains a significant clinical challenge.
• The tumor microenvironment plays a critical role in modulating ICI efficacy.

Purpose of the Study:

• To investigate the role of tumor-derived lactic acid in mediating resistance to PD-1 blockade therapy.
• To elucidate the mechanisms by which lactic acid affects immune cells within the tumor microenvironment.
• To identify potential therapeutic targets for overcoming ICI resistance.

Main Methods:

• Analysis of tumor microenvironment in preclinical models.
• Assessment of T regulatory cell (Treg) activity and CD8+ T cell function.
• In vivo studies evaluating the impact of lactic acid modulation on anti-PD-1 therapy response.

Main Results:

• Tumor-derived lactic acid was identified as a key mediator of PD-1 blockade resistance.
• Elevated lactic acid levels were found to enhance the suppressive function of T regulatory cells.
• Lactic acid impaired the cytotoxic activity of CD8+ T cells, compromising antitumor immunity.
• PD-1 blockade synergized with lactic acid to further augment Treg-mediated suppression.

Conclusions:

• Lactic acid is a critical factor contributing to resistance against PD-1 blockade immunotherapy.
• Targeting lactic acid metabolism or its downstream effects on immune cells may represent a viable strategy to enhance ICI efficacy.
• Understanding the interplay between cancer metabolism and immune responses is crucial for developing more effective cancer treatments.